RegeneRx Seeks Cosmeceutical Partners While Developing Drugs
This article was originally published in The Rose Sheet
Executive SummaryCash-strapped Maryland biotech firm RegeneRx is in talks with global cosmetics firms to develop products from its drug candidate molecule T?4 and hopes to see revenue from cosmeceuticals by 2010
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.